Braemar Hotels (BHR) Ranking: Graded

Braemar Hotels & Resorts (NYSE: BHR) owns genuinely gorgeous hotels inside a genuinely difficult structure: luxury resorts and urban trophies (Ritz-Carltons among them) advised by Ashford Inc., with leverage, preferred layers, and advisory fees standing between the assets and the common shareholder.

Grade note. Dividend not being paid. Braemar Hotels and Resorts has made no common dividend payment since December 31, 2025. Yield is not displayed until payments resume. Grade reduced 8 points. See every 2026 REIT dividend cut and liquidation.
Braemar Hotels & Resorts (BHR) Snapshot
Share Price (delayed)$1.66 -1.78%
Market Cap$114M
SectorHotels ยท Luxury

Market data updates automatically several times daily. Last price refresh: Sep 28, 2026. Fundamentals reviewed against Q1 2026 SEC filings.

Business Model

Luxury lodging has been the strongest RevPAR segment of the recovery, wealthy travel never really paused, and Braemar’s resort collection captures it. Above the assets sits the Ashford advisory structure: external management fees, preferred equity with priority claims, and a track record of financial engineering that the market prices with a durable discount.

The Honest Risk Section

Structure over substance: advisory fees and preferred dividends absorb cash before common holders see it, leverage amplifies the luxury segment’s inherent cyclicality, and governance history (across the Ashford complex) earns our framework’s heaviest related-party discount. Beautiful assets; the common equity is last in a long line.

Frequently Asked Questions

What hotels does Braemar own?

Luxury resorts and urban trophy hotels, including Ritz-Carlton and other five-star flags, the strongest-performing lodging segment.

Why does BHR trade so cheaply?

External advisory fees, preferred equity priorities, leverage, and governance history stack claims ahead of common shareholders, the discount is structural.

Analysis reflects disclosures through Q1 2026. Live market data updates automatically. Independent research, not investment advice.